Biomarkers have shown promising treatment for many psychiatric disorders and certain types of cancers. As one of the top CRO companies in the field of psychotropic drug development, Creative Biolabs has focused on various kinds of biomarkers development services for years and has accomplished numerous challenging projects in this field. Equipped with deep knowledge and experience in biomarker identification, we can offer high-quality custom biomarker development solutions for our worldwide clients.
Introduction to Biomarkers Development of Psychiatric Disorders
Biomarkers play a significant role in disease diagnosis, therapeutic effect monitoring, as well as generation of new therapies. Biomarker development in psychiatric disorders is challenging due to the complexity of these disorders, the absence of precise correlation data among disease-associated molecules, signaling pathways, and patient heterogeneity.
Fig.1 Classification of biomarkers based on its main clinical application. (García-Gutiérrez, 2020)
As a result, a wide collection of biomarker discovery technologies have been generated for sample processing, potential biomarker identification, and safety assessment. For example, proteomics-based methods have become a suitable way for biomarker profiling in different psychiatric diseases, because these methods make it easier to get samples and analyze data. Also, genomic-based methods play a critical role in revealing the pathogenesis of psychiatric disorders, discovering novel drugs in clinical treatment. In recent years, biomarkers have been classified into several types according to specific experimental purposes, such as diagnostic biomarker, monitoring biomarker, predictive biomarker, prognostic biomarker, as well as susceptibility biomarker.
Biomarkers Development Service of Psychiatric Disorders
Nowadays, biomarkers development has been considered the most significant step of new drug discovery. Creative Biolabs offers a full range of biomarkers development solutions for psychiatric disorders. Our labs equipped with state-of-the-art facilities and highly experienced staffs are available to assist in all areas of biomarker development projects, including but not limited to:
Fig.2 Multi-omics approach for the discovery and validation of biomarkers to probe multidimensional phases of the disease. (García-Gutiérrez, 2020)
Recent studies have demonstrated that laboratory-based markers, such as proteins, metabolites, and hormones, can be used for evaluating the severity of psychiatric disorders and predicting clinical responses to specific drugs. As a consequence, our expert team has established a panel of laboratory-based marker development assays to assist the treatment of psychiatric disorders. Our assays are dedicated to creating a well-mature platform to provide more effective markers in clinical use.
At Creative Biolabs, our integrated team has produced several psycho-immunological markers for studying the pathogenesis of different psychiatric disorders, including anxiety disorders, post-traumatic stress disorder, and schizophrenia. Up to now, different kinds of psycho-immunological markers, including cytokine, anticardiolipin antibodies (ACA), and interleukin, have been generated and confirmed by our scientists to diagnose patients with psychiatric disorders.
Recently, several novel neuroendocrine biomarkers have been developed based on many advanced technologies, such as dexamethasone-suppression testing (DST) and growth hormone (GH) testing, to diagnose psychiatric diseases. For instance, DST has been designed to detect the expression level change of cortisol in Cushing syndrome (CS). Nowadays, Creative Biolabs offers a wide array of neuroendocrine marker discovery services to design and assess the new class of neuroendocrine markers in different psychiatric disorders models.
Creative Biolabs can provide a panel of genetic marker development services to offer novel targets for psychiatric disorders characterization, diagnosis, as well as the generation of new therapies. In principle, our genetic markers are designed based on DNA or RNA molecules that have become important parameters to improve the clinical performance of drug interventions or other therapeutic.
As a reliable drug discovery company, Creative Biolabs is committed and proud to be part of this rewarding challenge by offering support to psychotropic drug discovery development and biomarker development to our clients. We are proud to partner with you on the journey of bringing novel candidate drugs of psychotropic diseases to the market. If you are interested in our services, please contact us for more details.
Reference
-
García-Gutiérrez, M. S., et al. Biomarkers in Psychiatry: Concept, Definition, Types, and Relevance to Clinical Reality. Frontiers in Psychiatry. 2020, 11: 432. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
